Quantum
Home > Boards > US Listed > Medical - Drugs >

Kitov Pharmaceuticals Hldgs L Sponsored ADR (KTOV)

KTOV RSS Feed
Add KTOV Price Alert      Hide Sticky   Hide Intro
Moderator: bUrRpPPP!, EM, finesand
Search This Board: 
Last Post: 11/19/2018 7:31:41 PM - Followers: 117 - Board type: Free - Posts Today: 0




Kitov Pharma (KTOV)

Market Cap: $16 Million
Cash $17 Million
Price: $1.44

Shares Out: 10.6 Million


Kitov Announces FDA Acceptance of NDA for KIT-302..........October 3, 2017
https://www.baystreet.ca/articles/research_reports/lifesci/Kitov100317.pdf

KIT-302 is a Treatment for Hypertension and Osteoarthritis Pain.
KIT-302 is a fixed dose combination drug comprised of the nonsteroidal anti-inflammatory drug (NSAID)celecoxib, and the well-known antihypertensive agent, amlodipine besylate. Celecoxib monotherapy often leads to hypertension, which if uncontrolled, can increase the risk of heart attack and stroke. KIT-302 is designed to provide a solution for physicians who avoid prescribing NSAIDs for osteoarthritis pain due to their hypertensive side effects. There is currently no single drug for the treatment of pain and hypertension, so, if approved, KIT-302 could be a unique product in the multibillion-dollar osteoarthritis market.

Expected Upcoming Milestones

¦Additional marketing agreements for the distribution of KIT-302
¦Q4 2017 – Top-line results from Phase III kidney function trial.
¦Q2 2018 – Expected FDA approval decision for KIT-302.




Presentation June 2017
http://kitovpharma.investorroom.com/download/KitovPresentation+June+2017+FINAL.pdf

KIT-302 is a combination drug that treats osteoarthritis pain and hypertension simultaneously

Primary efficacy endpoint achieved Lead drug candidate KIT-302 achieved its primary efficacy endpoint in a pivotal Phase III trial

Marketing potential Pipeline candidates address large, multi-billion dollar markets




Kitov Received a $2 Million Filing Waiver from FDA
http://kitovpharma.investorroom.com/news-releases?item=46

Kitov Pharmaceuticals Holdings Ltd. (NASDAQ: KTOV, TASE: KTOV), an innovative biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has granted Kitov a waiver related to the $2,038,100 New Drug Application (NDA 210045) filing fee for KIT-302. KIT-302 is Kitov's patented combination of Amlodipine Besylate-Celecoxib tablets, intended to treat osteoarthritis pain and hypertension simultaneously.

 

Products

Kitov’s current pipeline products, KIT-301 and KIT-302, are combination drugs that treat OA pain and HTN simultaneously. In December 2015, KIT-302 successfully achieved the primary efficacy endpoint for its Phase III clinical trial. In August 2016, the United States Patent Office issued a patent covering KIT-302.

Market

Of the 27 million Americans with OA, 50% also suffer from HTN, which is also a common side effect of stand-alone OA drugs. With no single medication currently treating both conditions, KIT-301 and KIT-302 are targeting this multi-billion dollar market.



Kitov Pharma’s Arthritis Drug Meets Main Goal in Late-Stage Study
http://jewishbusinessnews.com/2015/12/16/kitov-pharmas-arthritis-drug-meets-main-goal-in-late-stage-study/

“KIT-302 has the potential to address the multi-billion dollar market for the treatment of osteoarthritis pain and hypertension with one drug that reduces patients’ risk of suffering a heart attack or stroke, while also reducing cost for payers. There is currently no single medication on the market that treats both osteoarthritis pain and hypertension and thus, KIT-302 will be the only NSAID indicated both to treat pain and to reduce the risk of heart attack, stroke and death.”

Pain medications for osteoarthritis account for billions of dollars in annual sales globally. Most pain medications for osteoarthritis, including celecoxib which had global sales of $2.7 billion in 2014, are non-steroidal anti-inflammatory drugs (NSAIDs) which have the side effect of elevating blood pressure, and increasing the risk of heart attacks, strokes and death. Of the 27 million Americans who live with osteoarthritis, 13.5 million also suffer from hypertension, which also increases the risk of heart attack, stroke, and death.





Dec. 17, 2015 :  Kitov Pharmaceuticals Reports Additional Data from its Phase III Trial on the Beneficial Blood Pressure Effects of KIT-302
http://www.prnewswire.com/news-releases/kitov-pharmaceuticals-reports-additional-data-from-its-phase-iii-trial-on-the-beneficial-blood-pressure-effects-of-kit-302-300194664.html



November 20, 2015 : Kitov Pharmaceuticals Holdings Announces Pricing of U.S. Initial Public Offering and NASDAQ Listing
http://www.prnewswire.com/news-releases/kitov-pharmaceuticals-holdings-announces-pricing-of-us-initial-public-offering-and-nasdaq-listing-552301701.html



October 21, 2015 : Kitov Pharma Announces Completion of Patient Recruitment for the Phase III Clinical Trial for KIT-302
http://www.prnewswire.com/news-releases/kitov-pharma-announces-completion-of-patient-recruitment-for-the-phase-iii-clinical-trial-for-kit-302-535035241.html





 

Quantum
KTOV
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
KTOV News: Report of Foreign Issuer (6-k) 11/09/2018 04:38:33 PM
KTOV News: Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of American Depository Shares and Warrants o... 10/15/2018 08:00:00 AM
KTOV News: Report of Foreign Issuer (6-k) 10/11/2018 09:36:36 AM
KTOV News: Kitov Appoints Gil Efron as Deputy Chief Executive Officer and Chief Financial Officer 10/11/2018 08:26:00 AM
KTOV News: Report of Foreign Issuer (6-k) 09/26/2018 10:56:25 AM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#6634  Sticky Note Little Chart Update w/ Sabby Plunge finesand 09/21/18 12:57:09 PM
#6119  Sticky Note KITOV PHARMACEUTICALS - FULL DD EM 10/27/17 09:14:36 AM
#6683   we must be very close, considering all the finesand 11/19/18 07:31:41 PM
#6682   I'm wondering if they're not getting the upfront Carolina00 11/19/18 02:47:34 PM
#6681   Seems like the Market doesn't like the Moves fwb 11/19/18 02:17:04 PM
#6680   KTOV chart bUrRpPPP! 11/18/18 01:37:14 PM
#6679   Sounds reasonable. fwb 11/14/18 04:55:46 PM
#6678   It's actually around 26 million shares fully diluted. Carolina00 11/14/18 04:53:45 PM
#6677   So you think around $13.00 to $16.00 a Share? fwb 11/13/18 05:37:19 PM
#6676   What do yall think ktov would be valued Carolina00 11/13/18 09:34:54 AM
#6675   Gotcha, thanks! Carolina00 11/13/18 09:27:59 AM
#6674   15mm NSDAQ = 15mm TASE (1:1 ratio) It means that EM 11/13/18 08:14:19 AM
#6673   So is there 30 million shares outstanding? 15 Carolina00 11/13/18 08:11:31 AM
#6672   Agree 100%. MTH4 11/12/18 06:14:08 PM
#6671   I will. Everyone should. EM 11/12/18 04:32:57 PM
#6670   Vote against Isaac Israel as CEO in MTH4 11/12/18 02:24:59 PM
#6669   The Only Movement from KTOV since FDA Approval fwb 11/11/18 10:41:58 AM
#6668   Not sure how to interpret this last news EM 11/10/18 11:17:38 AM
#6667   Yep so the ratio will be 1:1 and EM 11/10/18 04:50:12 AM
#6666   12/19 AGM vote for 20-1 RS of ordinary bUrRpPPP! 11/09/18 08:30:04 PM
#6665   thanks...eom bUrRpPPP! 11/02/18 06:30:58 AM
#6664   What is the price now? $1.32 LOL DavidW2 11/01/18 10:37:03 PM
#6663   Little Update (Crossing TASE) finesand 11/01/18 08:32:25 PM
#6662   Little Chart Update Again (lowest RSI ever) finesand 10/30/18 05:48:00 PM
#6661   From your mouth to Gods ears!!! midastouch017 10/28/18 04:17:51 PM
#6660   Partnership will be signed. My guess is within EM 10/28/18 02:19:38 PM
#6659   Most companies that go silent are required during zj3001 10/28/18 12:05:03 PM
#6658   Trying to keep the faith here....its my biggest bUrRpPPP! 10/28/18 11:54:25 AM
#6657   I have not lost hope yet, but with midastouch017 10/28/18 07:51:08 AM
#6656   What happened with your points? Did the co got Amatuer17 10/28/18 07:04:49 AM
#6655   Was posting some smileys but they appeared as Locke1 10/28/18 06:39:57 AM
#6654   ?????? Locke1 10/28/18 06:37:46 AM
#6653   Yes, waiting for a miracle. Miracles have happened midastouch017 10/28/18 06:08:33 AM
#6652   Hey man, are you still here? ?? Locke1 10/28/18 02:19:53 AM
#6651   With the ongoing b.s. , who knows if Slax 10/26/18 12:31:30 PM
#6650   Probably they’re on a sabbatical, all together. ?? Locke1 10/26/18 12:23:33 PM
#6649   Yeah, I keep trying to reach them. To Slax 10/26/18 12:21:47 PM
#6648   Yes sir, you’re right. Volume is comical. We Locke1 10/26/18 12:15:31 PM
#6647   It's cheaper now than when they were dealing Slax 10/26/18 11:17:00 AM
#6646   This one has turned into a freaking horror Locke1 10/26/18 10:51:54 AM
#6645   Hi I am one of the long long Doubletree 10/11/18 11:23:32 AM
#6644   Kitov Appoints Gil Efron as Deputy Chief Executive EM 10/11/18 09:18:19 AM
#6643   Lol .... let’s hope the deputy ceo can EM 10/11/18 09:08:47 AM
#6642   They heard you. zj3001 10/11/18 08:42:13 AM
#6641   52 week low! Management do your job Chi99RT 10/10/18 01:42:23 PM
#6640   Wondering if maybe no partnership or buyout till MTH4 10/02/18 10:46:47 AM
#6639   Agree with you .... lot of errors in EM 10/02/18 09:41:47 AM
#6638   horrible blur, disregarding progress in legal proceeding and finesand 10/01/18 11:01:22 PM
#6637   Nice Seeking Alpha article 10/1 https://seekingalpha.com/article/4209192 bUrRpPPP! 10/01/18 01:53:41 PM
#6636   prelim settlement court doc filed 9/18 finesand 09/24/18 12:51:04 AM
#6635   Good summary of the possible catalysts in the EM 09/21/18 02:02:34 PM
#6634   Little Chart Update w/ Sabby Plunge finesand 09/21/18 12:57:09 PM
PostSubject